Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
== External links == Creatine+Kinase,+Mitochondrial+Form at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
The three substrates of this enzyme are L-2-aminoadipate 6-semialdehyde (L-allysine), oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are (S)-α-aminoadipic acid, reduced NADH, and a proton. This enzyme can also use nicotinamide adenine dinucleotide phosphate as its cofactor. The enzyme participates in lysine biosynthesis and biodegradation.
=== Precision medicine === Graphene oxide has been studied for its promising uses in a wide variety of nanomedical applications including tissue engineering, cancer treatment, medical imaging, and drug delivery. Its physiochemical properties allow for a structure to regulate the behaviour of stem cells, with the potential to assist in the intracellular delivery of DNA, growth factors, and synthetic proteins that could allow for the repair and regeneration of muscle tissue. Due to its unique behaviour in biological environments, GO has also been proposed as a novel material in early cancer diagnosis. It has also been explored for its uses in vaccines and immunotherapy, including as a dual-use adjuvant and carrier of biomedical materials. In September 2020, researchers at the Shanghai National Engineering Research Center for Nanotechnology in China filed a patent for use of graphene oxide in a recombinant vaccine under development against SARS-CoV-2.
He says he will be able to find "common ground" with the US president-elect. MP for Runcorn and Helsby, Mike Amesbury, is to be charged with common assault, following a police investigation into video footage that appeared to show him punching a man to the ground in the street. Amesbury was suspended from the Labour Party after the video emerged. 8 November – Jonathan Powell, a former Chief of Staff to Tony Blair, is appointed as the UK's national security adviser, replacing Sir Tim Barrow. 9 November – Former Health Secretary Alan Milburn, who served in the Blair government, is appointed as a non-executive director on the board of the Department of Health. 10 November – Treasury minister Darren Jones tells BBC One's Sunday with Laura Kuenssberg the UK government's commitment to Ukraine is "resolute" amid concerns Donald Trump could push the country into giving up territory to Russia once he becomes president. First Minister of Northern Ireland Michelle O'Neill becomes the first senior Sinn Féin figure to take part in an official Remembrance Sunday ceremony, held in Belfast. 11 November – The Terminally Ill Adults (End of Life) Bill, which would allow terminally ill people in England and Wales with less than six months to live to seek assistance in ending their lives, with the consent of two doctors and a High Court judge, is published. At the invitation of French president Emmanuel Macron, Starmer travels to France to mark Armistice Day at the Tomb of the Unknown Soldier, then holds talks with Macron to affirm the UK and France's commitment to supporting Ukraine.
Sources: en.wikipedia.org
One factor that has an important effect on this electrical activity of gonadotrophs is the gonadotropin-releasing hormone (GnRH). GnRH is a hormone released by the hypothalamus, and it is responsible for signaling gonadotrophs to release gonadotropins FSH and LH. GnRH binds to gonadotropin-releasing hormone receptors (GnRHR), which is a G-protein coupled receptor, and signals the oscillation of calcium that hyperpolarizes gonadotropic cell membranes. This oscillation of calcium ions occurs through the resultant signaling cascade of the GnRH binding to the GnRHR in the plasma membrane of the gonadotroph. The G-protein associated with the GnRHR is activated by the binding of GnRH, which results in increased phospholipase C (PLC) activity in the plasma membrane. PLC cleaves phosphatidylinositol-4,5-biophosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG) signals. DAG activates protein kinase C (PKC), which phosphorylates proteins, and IP3 binds to IP3 receptors on the membrane of the endoplasmic reticulum (ER). This binding results in the release of intracellular calcium ions stored within the ER. Therefore, this increase in calcium ions signals the synthesis of secretion of FSH and LH in gonadotrophs. Overall, the fluctuation of calcium levels that is activated by the electrical activity and the signaling pathway within gonadotropic cells collectively contribute to the synthesis and release of gonadotropins that will serve an endocrine function in the reproductive system.
== Classical era == Because silver was extensively used as a decorative material and an exchange medium, lead deposits came to be worked in Asia Minor from 3000 BC; later, lead deposits were developed in the Aegean and Laurion. These three regions collectively dominated production of mined lead until c. 1200 BC. Beginning c. 2000 BC, the Phoenicians worked deposits in the Iberian peninsula; by 1600 BC, lead mining existed in Cyprus, Greece, and Sardinia. Rome's territorial expansion in Europe and across the Mediterranean, and its development of mining, led to it becoming the greatest producer of lead during the classical era, with an estimated annual output peaking at 80,000 tonnes. Like their predecessors, the Romans obtained lead mostly as a by-product of silver smelting. Lead mining occurred in central Europe, Britain, Balkans, Greece, Anatolia, Hispania, the latter accounting for 40% of world production.
=== Pharmacodynamics === Levomethadone has approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity. Accordingly, it is about twice as potent as methadone by weight and its effects are virtually identical in comparison. In addition to its activity at the opioid receptors, levomethadone has been found to act as a weak competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor complex and as a potent noncompetitive antagonist of the α3β4 nicotinic acetylcholine (nACh) receptor.
=== Life Peer === Baroness Dame Audrey Caroline Emerton, , Chief Officer, Care in the Community, and Co-Chairman, Medical Board, St. John Ambulance; Chairman, Brighton Health Care NHS Trust. Baron Raj Kumar Bagri, , Chairman, London Metal Exchange, and Chairman, MetDist Ltd. Sir Andrew Lloyd Webber, Composer.
One Mesopotamian myth, a historiographic poem entitled "The curse of Akkad: the Ekur avenged", explains how the empire created by Sargon of Akkad fell and the city of Akkad was destroyed. The myth was written hundreds of years after Naram-Sin's life and is the poet's attempt to explain how the Gutians succeeded in conquering Sumer. After an opening passage describing the glory of Akkad before its destruction, the poem tells of how Naram-Sin angered the chief god Enlil by plundering the Ekur (Enlil's temple in Nippur.) In his rage, Enlil summoned the Gutians down from the hills east of the Tigris, bringing plague, famine and death throughout Mesopotamia. Food prices became vastly inflated, with the poem stating that 1 lamb would buy only half a sila (about 425 ml or 14.4 US fl oz) of grain, half a sila of oil, or half a mina (about 250 g or 8.8 oz) of wool. To prevent this destruction, eight of the gods (namely Inanna, Enki, Sin, Ninurta, Utu, Ishkur, Nusku, and Nidaba) decreed that the city of Akkad should be destroyed in order to spare the rest of Sumer and cursed it.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.